Home › Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen
 

Keywords :   


Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

2015-07-06 15:29:07| Biotech - Topix.net

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. , announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen for the treatment of patients with Familial Chylomicronemia Syndrome . FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis.

Tags: drug designation fda obtains

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
07.11Tropical Depression Fourteen-E Forecast Discussion Number 5
More »